1 January 2011PatentsDaniel Yonan and Mark Fox Evens

Big pharma and Section 337: the next frontier

With its March 16, 2011 vote to institute Investigation No. 337-TA-766, entitled Certain Gemcitabine and Products Containing Same, the United States International Trade Commission (commission) quite possibly opened a new frontier for enforcing non-Orange Book listed patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

Tesla ‘Robotaxi’ and ‘Cybercab’ TMs rebuffed by USPTO on eve of launch

UK-India trade deal is ‘missed opportunity’, say industry bodies

AI, lipstick deals and mental health: What’s on CITMA president’s radar?

WATCH: Recent developments in design patent law

SEPs now searchable on WIPO’s global patent database

INTA 2025: San Diego to host largest post-COVID Annual Meeting

'Nothing can stand in the way of our work': Ukraine resumes IP system

Foley adds five-partner team from Perkins Coie and K&L Gates

Big pharma and Section 337: the next frontier

Editor's picks

Editor's picks

More articles